natgillin/translations-raw huggingface dataset:
Method according to claim 4 or 5 characterized by the fact that said steps of selecting and storing are executed through a "drag&drop" of the multimedia content (R1,..., RN) from said area (A1,..., An) to the storage folder (C). 
Metoda prema patentnom zahtjevu 4 ili 5, naznačena time da su navedeni koraci odabira i spremanja izvršeni „povlačenjem i ispuštanjem" multimedijalnog sadržaja (R1,..., RN) s navedenog odjeljka (A1, …, An) u mapu za pohranu (C).
Method according to claim 4 characterized by the fact that said storage folder (C) stores multimedia contents (R1,..., RN) associated to different types (T1,..., TN). 
Metoda prema patentnom zahtjevu 4, naznačena time da se u navedenoj mapi za pohranu (C) spremaju multimedijalni sadržaji (R1,..., RN) povezani s raznim vrstama (T1,..., TN).
detecting an Internet address of a multimedia content associated (R1,..., RN) erroneously to a first (T1) of said type (T1,..., TN) and detecting a second type (T2) to be associated to said Internet address; 
pronalaženje internetske adrese multimedijalnog sadržaja (R1,..., RN) pogrešno povezane s prvom (T1) od navedenih vrsta (T1,..., TN) te pronalaženje druge vrste (T2) koju povezati s navedenom internetskom adresom;
storing said tags ("yyy"), said internet addresses and/or said added internet address in a database of said internet provider (3). 
spremanje navedenih oznaka (,,yyy“), navedenih internetskih adresa i/ili navedenih dodanih internetskih adresa u bazu podataka navedenog pružatelja internetskih usluga (3).
Use of an antibody or antigen-binding fragment of an antibody according to anyone of claims 1 to 5 in the manufacture of a medicament for use to attenuate or inhibit an IL-6-mediated disease or disorder in a human, where the IL-6-mediated disease or disorder is arthritis, an inflammatory bowel disease or systemic lupus erythematosus. 
Upotreba antitijela ili njegovog fragmenta koji se veže na antigen prema bilo kojem od patentnih zahtjeva 1 od 5, naznačen time, da se upotrebljava u proizvodnji lijeka čijom uporabom se smanjuje ili inhibira bolest ili poremećaja u čovjeka kojima je IL-6 medijator pri čemu je bolest ili poremećaj kojima je IL-6 medijator artritis, upalna bolest crijeva ili sistemski eritematozni lupus.
A delta-like ligand 4 (Dll4) antagonist for use in preventing or reducing blood vessel loss or promoting productive angiogenesis, or both, in a subject having an ischemic injury or vascular insufficiency, wherein the Dll4 antagonist comprises an antibody or antibody fragment that specifically binds Dll4 and blocks the binding of Dll4 to a Notch receptor or comprises the extracellular domain of Dll4, optionally connected to a multimerizing component. 
Antagonist liganda DII4 (tipa Delta4) antagonist za uporabu u prevenciji ili smanjenju gubitka krvnih žila ili promicanju produktivne angiogeneze, ili oboje, u subjektu koji ima ishemijsku ozljedu ili vaskularnu insuficijenciju, naznačen time, da DII4 antagonist sadrži antitijelo ili fragment antitijela koji specifično veže DII4 i blokira vezivanje DII4 na Notch receptor ili obuhvaća ekstracelularnu domenu DII4, opcionalno spojen na multimerizirajuću komponentu.
The Dll4 antagonist for use according to claim 10, wherein the antibody or antibody fragment is a single chain antibody, an Fab, or an F(ab')2. 
DII4 Antagonist za uporabu u skladu s patentnim zahtjevom 10, naznačen time, da je antitijelo ili fragment antitijela jednolančano antitijelo, Fab ili F (ab')2.
removing the amino-protecting group, P, from the compound of formula 3 or a salt thereof, to provide a compound of formula I or a salt thereof. 
uklanjanje amino-zaštitne skupine, P, iz spoja formule 3 ili njegove soli, da se dobije spoj formule I ili njegova sol.
(a') reacting a compound of formula 4: or a salt thereof, with a reducing agent to provide a compound of formula 5: or a salt thereof; and 
(a') reakcije spoja prema formuli 4: [image] ili njegove soli, s redukcijskim sredstvom kako bi se dobio spoj prema formuli 5:
(b') converting the hydroxyl group of the compound of formula 5 or a salt thereof, into a leaving group, L, to provide a compound of formula 1 or a salt thereof. 
[image] ili njegova sol; i (b') pretvaranje hidroksil skupine spoja prema formuli 5 ili njegove soli, u izlaznu skupinu, L, čime se dobiva spoj formule 1 ili njegova sol.
the amination of 1,1-cyclohexanediacetic acid anhydride by reaction with aqueous NH3 at a temperature comprised between 10 and 25°C by using a NH3/nhydride molar ratio lower than 3; 
aminaciju anhidrida 1,1-cikloheksandioctene kiseline putem reakcije s vodenim NH3 na temperaturi između 10 i 25°C tako da se koristi molarni omjer NH3/anhidrid manji od 3;
A process according to claim 15 wherein the amination of 1,1-cyclohexanediacetic acid anhydride takes place by reaction with ammonia in aqueous solution with a concentration 28%. 
Postupak prema zahtjevu 15 gdje se aminacija anhidrida 1,1-cikloheksandioctene kiseline odvija reakcijom s amonijakom u vodenoj otopini u koncentraciji od 28%.
A process according to claim 14 wherein the acidification step is carried out with concentrated or gaseous hydrochloric acid. 
Postupak prema zahtjevu 14 gdje se korak zakiseljavanja provodi s koncentriranom ili plinovitom klorovodičnom kiselinom.
A process according to claim I further comprising the transformation of 1,1-cyclohexanediacetic acid into the corresponding anhydride. 
Postupak prema zahtjevu 1 koji dalje obuhvaća pretvorbu 1,1-cikloheksandioctene kiseline u odgovarajući anhidrid.
A process according to claim 21 wherein the transformation of 1,1-cyclohexanediacetic acid into the corresponding anhydride is carried out by reaction with acetic anhydride in the presence of an organic solvent. 
Postupak prema zahtjevu 21 gdje se pretvorba 1,1-cikloheksandioctene kiseline u odgovarajući anhidrid provodi reakcijom s octenim anhidridom u prisutnosti organskog otapala.
A process according to claim 22 wherein the organic solvent is toluene. 
Postupak prema zahtjevu 22 gdje je organsko otapalo toluen.
A process for the preparation of 1,1-cyclohexanediacetic acid monoamide comprising: 
Postupak pripreme monoamida 1,1-cikloheksandioctene kiseline koji obuhvaća:
the amination of 1,1-cyclohexanediacetic acid anhydride by reaction with aqueous NH3 at a temperature comprised between 10 and 25°C by using a NH3/anhydride molar ratio lower than 3; 
aminaciju anhidrida 1,1-cikloheksandioctene kiseline putem reakcije s vodenim NH3 na temperaturi između 10 i 25°C tako da se koristi molarni omjer NH3/anhidrid manji od 3;
A process according to claim 14 further comprising the transformation of 1,1-cyclohexanediacetic acid into the corresponding anhydride. 
Postupak prema zahtjevu 14 koji dalje obuhvaća pretvorbu 1,1-cikloheksandioctene kiseline u odgovarajući anhidrid.
An acid addition salt of a compound of the formula (1) which is a salt formed with L-lactic acid. 
Kiselinska adicijska sol spoja formule (1) [image] koja je sol dobivena s mliječnom kiselinom.
An acid addition salt of a compound of the formula (1) which is a salt formed with lactic acid. 
Kiselinska adicijska sol spoja formule (1) [image] koja je sol dobivena s mliječnom kiselinom.
An acid addition salt according to claim 1 which is a salt formed with L-lactic acid. 
Kiselinska adicijska sol prema zahtjevu 1, koja je sol dobivena s L-mliječnom kiselinom.
subjecting the compound of formula (3) to catalytic hydrogenation to remove the protecting groups PG and, when A-B is C=CH2, reduce the group A-B to an isopropyl group and thereafter, where the compound of formula (2) is prepared in the form of a free base, optionally converting the free base to an acid addition salt. 
podvrgavanje spoja formule (3) katalitičkoj hidrogenaciji radi uklanjanja zaštitnih skupina PG i, kada A-B označava C=CH2, reduciranja skupine A-B na izopropilnu skupinu i nakon toga, hdje se spoj formule (2) pripravlja u obliku slobodne baze, izborno pretvaranja slobodne baze u kiselinsku adicijsku sol.
subjecting the compound of formula (9) to catalytic hydrogenation to remove the protecting groups PG and, when R4' is C2-5 alkenyl, reduce the group R4' to C2-5 alkyl; and thereafter, where the compound of formula (6) is prepared in the form of a free base, optionally converting the free base to an acid addition salt. 
podvrgavanje spoja formule (9) katalitičkoj hidrogenaciji radi uklanjanja zaštitnih skupina PG i, kada R4' označava C2-5 alkenil, reduciranja skupine R4' na C2-5 alkil; i nakon toga, gdje se spoj formule (6) pripravlja u obliku slobodne baze, izborno pretvaranja slobodne baze u kiselinsku adicijsku sol.
in treating a disease or condition comprising or arising from abnormal cell growth in a mammal; or 
u liječenju bolesti ili stanja koje se sastoji od ili proizlazi iz abnormalnog rasta stanica u sisavaca; ili
for use in the treatment of a proliferative disorders selected from a carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, gastrointestinal system, or skin; a hematopoieitic tumour of lymphoid lineage; a hematopoieitic tumour of myeloid lineage; thyroid follicular cancer; a tumour of mesenchymal origin; a tumour of the central or peripheral nervous system; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoacanthoma; thyroid follicular cancer; or Kaposi's sarcoma; or 
za primjenu u liječenju proliferativnih poremećaja koji mogu biti rak mjehura, dojke, debelog crijeva, bubrega, epiderma, jetara, pluća, jednjaka, žučnog mjehura, jajnika, gušterače, želuca, grlića maternice, štitnjače, prostate, gastrointestinalnog sustava ili kože; hematopoetski tumor limfnog sustava; hematopoetski tumor mijeloidne linije; folikularni rak štitnjače; tumor mezenhimalnog podrijetla; tumor središnjeg perifernog živčanog sustava; xeroderma pigmentosum; keratoakantom; folikularni rak štitnjače; ili Kapošijev sarkom; ili
in the manufacture of a medicament for the prophylaxis or treatment of a fungal, protozoal or parasitic disease state or condition, other than a disease state or condition due to Plasmodium falciparum; or 
u proizvodnji lijeka za prevenciju i liječenje gljivičnih, protozoalnih ili parazitskih oboljenja ili stanja, koja nisu oboljenje ili stanje uzrokovano parazitom Plasmodium falciparum; ili
in the manufacture of a medicament for use in the reduction or elimination of pain in a patient suffering from pain; or 
u proizvodnji lijeka za primjenu kod smanjenja ili eliminacije boli u bolesnika koji pate od boli; ili
in the manufacture of a medicament for the treatment of any one or more of nociception, somatic pain, visceral pain, acute pain, chronic pain, hyperalgesia, allodynia, post operative pain, pain due to hypersensivity, headache, inflammatory pain, neurological pain, musculoskeletal pain, cancer related pain or vascular pain; or 
u proizvodnji lijeka za liječenje jednog ili više od sljedeće navedenog: nocicepcija, somatska bol, visceralna bol, akutna bol, kronična bol, hiperalgezija, alodinija, postoperativna bol, bol zbog preosjetljivosti, glavobolja, upalna bol, neurološka bol, mišićno-koštana bol, bol povezana s rakom ili vaskularna bol; ili
in a method of preventing or reducing neuronal damage in a patient suffering from stroke, which method comprises administering to the patient an effective neuroprotective amount of the compound, crystalline form or acid addition salt; or 
u metodi suzbijanja ili ublažavanja oštećenja neurona u bolesnika koji su imali moždani udar, koja metoda obuhvaća davanje pacijentu količine spoja, kristalnog oblika ili kiselinske adicijske soli; ili
in the manufacture of a medicament for the prevention or reduction of risk of stroke in patients at risk for stroke; or 
u proizvodnji lijeka za suzbijanje ili smanjivanje rizika od moždanog udara u bolesnika koji su izloženi riziku od moždanog udara; ili
in the prophylaxis or treatment of a viral infection or viral disease; or 
u prevenciji ili liječenju virusnih infekcija ili virusnih oboljenja; ili
in a method of blocking or inhibiting viral replication in a host organism, which method comprises administering to the host organism the compound, crystalline form or acid addition salt; or 
u metodi za primjenu u blokiranju ili inhibiciji virusne replikacije u tijelu domaćinu, koja metoda obuhvaća davanje tijelu domaćinu spoja, kristalnog oblika ili kiselinske adicijske soli; ili
in a method for the treatment of a cancer which method comprises administering to a subject in need thereof the compound, crystalline form or acid addition salt, which method is characterized by the absence of drug resistance; or 
u metodi za liječenje raka, koja obuhvaća davanje potrebitom subjektu spoja, kristalnog oblika ili kiselinske adicijske soli, a koja metoda je naznačena odsutnošću otpornosti na lijek; ili
in a method for the prophylaxis or treatment or alleviation or reduction of the incidence of a disease state or condition mediated by Hsp90 in a subject undergoing treatment with a therapeutic agent, which method comprises administering to the subject the compound, crystalline form or acid addition salt, wherein the disease state or condition mediated by Hsp90 is the development of resistance to the said therapeutic agent; or 
u metodi za prevenciju ili liječenje ili ublažavanje ili smanjivanje nastanka oboljenja ili stanja vezanih uz nastanak Hsp90 u subjekata koji se liječe terapijskim lijekom, a koja metoda obuhvaća davanje subjektu spoja, kristalnog oblika ili kiselinske adicijske soli, s tim da je bolest ili oboljenje vezano uz nastanak Hsp90 predstavlja razvoj otpornosti na navedeni terapijski lijek; ili
The use of a salt according to any one of claims 1 to 3 for the manufacture of a medicament for the treatment of a disease, condition or disorder as defined in claims 10. 
Primjena soli prema jednom od zahtjeva 1 do 3 za proizvodnju lijeka za liječenje bolesti, stanja ili poremećaja pobliže opisanim u zahtjevu 10.
the reaction of a compound of the formula (11): with (a) acetic anhydride in the presence of 4-dimethylaminopyridine, followed by (b) trifluoromethanesulphonic acid and optionally acetyl chloride; or 
reakciju spoja formule (11): [image] s (a) anhidridom octene kiseline u prisutnosti 4-dimetil-aminopiridina, kojem slijedi (b) trifluorometan-sulfonska kiselina i izborno acetil-klorid; ili
the reaction of a compound of the formula (11) with acetyl chloride in the presence of a cationic ion-exchange resin. 
reakciju spoja formule (11) s acetil-kloridom u prisutnosti kationskog ionskog izmjenjivača.
the reaction of a compound of the formula (24): wherein PG is a protecting group and LG1 is a leaving group, with a compound of the formula (22); or 
reakciju spoja formule (24): [image] naznačen time da je PG zaštitna skupina i LG1 odlazeća skupina, sa spojem formule (22); ili
the reaction of a compound of the formula (25): wherein PG is a protecting group, with a compound of the formula (22) as defined above under reductive amination conditions; 
reakciju spoja formule (25): [image] naznačen time da je PG zaštitna skupina, sa spojem formule (22) prema gornjoj definiciji, pod uvjetima aminacije, i nakon toga uklanjanje zaštitne skupine PG.
A pharmaceutical composition which comprises a sodium channel blocker selected from the group consisting of lamotrigine and crobenetine in combination with a selective serotonin uptake inhibitor selected from the group consisting of fluoxetine, paroxetine, sertraline, escitalopram and citalopram. 
Farmaceutski sastav koji sadrži natrijev blokator kanala izabran iz skupine koja je sastavljena od lamotrigina i krobenetina u kombinaciji sa selektivnim inhibitorom unosa serotonina izabranog iz skupine koja se sastoji od fluoksetina, paroksetina, sertralina, escitaloprama i citaloprama.
A pharmaceutical composition according to claim 1, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is lamotrigine. 
Farmaceutski sastav temeljem zahtjeva 1, pri čemu je selektivni inhibitor unosa serotonina fluoksetin, a natrijev blokator kanala je lamotrigin.
A pharmaceutical composition according to claim 1, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is crobenetine. 
Farmaceutski sastav temeljem zahtjeva 1, pri čemu je selektivni inhibitor unosa serotonina fluoksetin, a natrijev blokator kanala je krobenetin.
A pharmaceutical composition according to claim 1, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is lamotrigine. 
Farmaceutski sastav temeljem zahtjeva 1, pri čemu je selektivni inhibitor unosa serotonina sertralin, a natrijev blokator kanala je lamotrigin.
A pharmaceutical composition according to claim 1, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is crobenetine. 
Farmaceutski sastav temeljem zahtjeva 1, pri čemu je selektivni inhibitor unosa serotonina sertralin, a natrijev blokator kanala je krobenetin.
The use of a sodium channel blocker selected from the group consisting of lamotrigine and crobenetine and a selective serotonin uptake inhibitor inhibitor selected from the group consisting of fluoxetine, paroxetine, sertraline, escitalopram and citalopram in a process for the preparation of a pharmaceutical composition suitable for the treatment and/or the prevention of drug or alcohol addiction, incontinence of faeces and urine, inflammation, itching, intracranial edema, ischemia and/or subsequent damage caused by reperfusion or retinopathy, as a complication of glaucoma in mammals. 
Upotreba natrijevog blokatora kanala izabranog iz skupine koja se sastoji od lamotrigina i krobenetina i selektivnog inhibitora unosa serotonina izabranog iz skupine koja se sastoji od fluoksetina, paroksetina, sertralina, escitaloprama i citaloprama u postupku pripreme farmaceutskog sastava pogodnog za liječenje i/ili prevenciju ovisnosti o drogama ili alkoholu, inkotinencije izmeta i urina, upala, svrbeža, intrakranijalnih edema, ishemije i/ili naknadne štete uzrokovane reperfuzijom ili retinopatijom, kao komplikacijom glaukoma kod sisavaca.
The use of a sodium channel blocker selected from the group consisting of lamotrigine and crobenetine and a selective serotonin uptake inhibitor inhibitor selected from the group consisting of fluoxetine, paroxetine, sertraline, escitalopram and citalopram in a process for the preparation of a pharmaceutical composition suitable for the treatment and/or prevention of diseases in mammals, which involve chronic pain or epilepsy, or symptoms or diseases deriving from disorders and/or injuries of the motor system. 
Upotreba natrijevog blokatora kanala izabranog iz skupine koja se sastoji od lamotrigina i krobenetina i selektivnog inhibitora unosa serotonina izabranog iz skupine koja se sastoji od fluoksetina, paroksetina, sertralina, escitaloprama i citaloprama u postupku pripreme farmaceutskog sastava pogodnog za liječenje i/ili prevenciju bolesti kod sisavaca, koje uključuju kroničnu bol ili epilepsiju, ili simptome ili bolesti koje proizlaze od poremećaja i/ili ozljeda motoričkog sustava.
A compound according to claim 1 and/or a pharmaceutically acceptable salt thereof and at least one anti-neoplastic agent, such as one selected from a group consisting of anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, and cell cycle signaling inhibitors, for use in co-administration to treat cancer. 
Spoj u skladu s patentnim zahtjevom 1 i/ili njegova farmaceutski prihvatljiva sol i najmanje jedno antineoplastično sredstvo, poput onog koje se bira iz skupine koju čine antimikrotubulska sredstva, koordinacijski kompleksi platine, alkilirajuća sredstva, antibiotska sredstva, inhibitori topoizomeraze II, antimetaboliti, inhibitori topoizomeraze I, hormoni i hormonski analozi, inhibitori puta prijenosa signala, inhibitori nereceptorskih tirozinskih kinaza kao inhibitori angiogeneze, imunoterapijska sredstva, proapoptotska sredstva, i inhibitori signala staničnog ciklusa, naznačeni time što su namijenjeni zajedničkoj primjeni u liječenju raka.
A compound for use according to claim 5, wherein the disease state is selected from a group consisting of: multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis, brain infection/inflammation, meningitis and encephalitis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se bolesno stanje bira iz skupine koju čine: multipla skleroza, psorijaza, reumatoidni artritis, sistemni eritematozni lupus, upalna bolest crijeva, upala pluća, tromboza, infekcija/upala mozga, meningitis i encefalitis.
A compound for use according to claim 5, wherein the disease state is selected from a group consisting of: Alzheimer's disease, Huntington's disease, CNS trauma, stroke and ischemic conditions. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se bolesno stanje bira iz skupine koju čine: Alzheimerova bolest, Huntingtonova bolest, ozljeda CNS-a, inzult i ishemična stanja.
A compound for use according to claim 6, wherein the disease state is selected from a group consisting of: atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure and vasoconstriction. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se bolesno stanje bira iz skupine koju čine: ateroskleroza, hipertrofija srca, disfunkcija kardiomiocita, povišeni krvni tlak i vazokonstrikcija.
A compound for use according to claim 5, wherein the disease state is selected from a group consisting of: chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, antiogenesis, invasion metastasis, melanoma, Karposi's sarcoma, acute and chronic bacterial and virual infections, sepsis, transplantation rejection, graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung, and lung airways inflammation. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se bolesno stanje bira iz skupine koju čine: kronična opstruktivna plućna bolest, anafilaktički šok, fibroza, psorijaza, alergijske bolesti, astma, inzult, ishemija-reperfuzija, agregacija/aktivacija trombocita, atrofija/hipertrofija skeletnih mišića, novačenje leukocita u tkivu raka, antiogeneza, invazivna metastaza, melanom, Kaposijev sarkom, akutne i kronične bakterijske i virusne infekcije, sepsa, odbacivanje transplantacije, odbacivanje presatka, glomeruloskleroza, glomerulonefritis, progresivna fibroza bubrega, ozljede endotela i epitela u plućima, te upala dišnih putova pluća.
A compound for use according to claim 11 wherein the cancer is selected from a group consisting of: ovarian cancer, pancreatic cancer, breast cancer, prostate cancer and leukemia. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što se rak bira iz skupine koju čine: rak jajnika, rak gušterače, rak dojke, rak prostate i leukemija.